Barker SS - Search Results

1

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.

Stinchcombe TE, Borghaei H, Barker SS, Treat JA, Obasaju C. Stinchcombe TE, et al. Among authors: barker ss. Clin Lung Cancer. 2016 Jan;17(1):1-9. doi: 10.1016/j.cllc.2015.07.002. Epub 2015 Jul 30. Clin Lung Cancer. 2016. PMID: 26340853 Review.

2

Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.

Simon GR, Manegold C, Barker SS, Treat JA, Visseren-Grul C, Obasaju C. Simon GR, et al. Among authors: barker ss. Clin Lung Cancer. 2013 Nov;14(6):601-8. doi: 10.1016/j.cllc.2013.06.001. Epub 2013 Aug 6. Clin Lung Cancer. 2013. PMID: 23921171 Review.

3

Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.

Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C. Choy H, et al. Lung Cancer. 2015 Mar;87(3):232-40. doi: 10.1016/j.lungcan.2014.12.003. Epub 2015 Jan 14. Lung Cancer. 2015. PMID: 25650301 Review.

4

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.

Hess LM, Brnabic A, Mason O, Lee P, Barker S. Hess LM, et al. J Cancer. 2019 Jun 9;10(16):3717-3727. doi: 10.7150/jca.32205. eCollection 2019. J Cancer. 2019. PMID: 31333789 Free PMC article. Review.

5

Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.

Jennings EM, Camidge DR, Gadgeel S, Barker S. Jennings EM, et al. Clin Lung Cancer. 2024 Mar;25(2):91-99. doi: 10.1016/j.cllc.2023.11.014. Epub 2023 Dec 5. Clin Lung Cancer. 2024. PMID: 38135566 Review.

6

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.

Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Drilon A, et al. Among authors: barker ss. J Clin Oncol. 2023 Jan 10;41(2):385-394. doi: 10.1200/JCO.22.00393. Epub 2022 Sep 19. J Clin Oncol. 2023. PMID: 36122315 Free PMC article. Clinical Trial.

7

[No title available]

[No authors listed] [No authors listed] PMID: 38580250

8

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.

De Braud F, Deschler-Baier B, Morris JC 3rd, Worden F, Han Y, Kiiskinen U, Jen MH, Barker SS, Szymczak S, Gilligan AM. De Braud F, et al. Among authors: barker ss. Cancers (Basel). 2023 Dec 27;16(1):140. doi: 10.3390/cancers16010140. Cancers (Basel). 2023. PMID: 38201566 Free PMC article.

9

Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases.

Liao CY, Gonzalez-Ferrer C, Whipple S, Peterson PM, Barker SS, Bhandari NR, Wang F. Liao CY, et al. Among authors: barker ss. Cancers (Basel). 2024 Nov 15;16(22):3835. doi: 10.3390/cancers16223835. Cancers (Basel). 2024. PMID: 39594790 Free PMC article.

10

Incidence and Management of Olaratumab Infusion-Related Reactions.

Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Van Tine BA, et al. Among authors: barker ss. J Oncol Pract. 2019 Nov;15(11):e925-e933. doi: 10.1200/JOP.18.00761. Epub 2019 Jul 3. J Oncol Pract. 2019. PMID: 31268811 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters